



Citi Pharma Limited

February 27, 2023

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Financial results for the 2nd quarter ended December 31, 2022.

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on February 27, 2023 at Lahore have approved the financial statements for the 2nd quarter ended on December 31, 2022 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

Financial results of the company for the 2nd quarter ended December 31, 2022 are enclosed.

While reviewing the Company financial performance for the half year ended, the Board appreciated the efforts of the management in the area of operations.

In the period under review net sales of the company has improved to Rs. 6,170 million as compared to Rs. 4,841 million in the corresponding period of the last period and registered a growth of 27%. Similarly, the Gross Profits has improved to Rs. 915 million as compared to half yearly financial statements ended December 31, 2021 of Rs. 701 million. Net profit of the company has improved to Rs. 440 million as compared to Rs. 343 million, an increase of almost 28% in spite of net exchange loss of Rs. 74 million due to continued devaluation of the Pak Rupee.

The Earning per share of the company also improved from Rs. 1.52 per share to Rs. 1.93 per share almost an increase of 26% from last period. The financial results of the company are as follows:

Quarterly report of the Company for the quarter ended December 31, 2022 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

Muhammad Riaz
Company Secretary
& Head of Legal



CC: Executive Director/HOD,
Offsite-II Department, Supervision Division,
Securities & Exchange Commission of Pakistan,
63, NIC Building, Jinnah Avenue, Blue Area, Islamabad



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2022

	Three month ended		Six Month Ended	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
-----Rupees-----				
Sales- Net	3,052,797,729	2,850,278,592	6,170,872,085	4,841,231,409
Cost of Sales	(2,507,759,970)	(2,445,219,540)	(5,255,444,173)	(4,139,830,800)
Gross Profit	545,037,759	405,059,052	915,427,912	701,400,609
Administrative Expenses	51,873,819	43,832,345	101,588,824	203,720,687
Selling Expenses	32,818,897	28,940,392	70,482,274	54,359,913
	(84,692,716)	(72,772,737)	(172,071,098)	(258,080,600)
Operating Profit	460,345,042	332,286,314	743,356,813	443,320,008
Financial Charges	35,451,281	(25,925,319)	(121,602,607)	(34,127,097)
	495,796,323	306,360,995	621,754,206	409,192,911
Other Income/(Loss)	4,935,455	58,402,733	52,533,589	89,254,858
	500,731,778	364,763,727	674,287,795	498,447,768
Other Expenses	(38,150,815)	(24,596,263)	(42,370,485)	(33,360,465)
Profit Before Taxation	462,580,963	340,167,464	631,917,310	465,087,303
Taxation	(167,752,676)	(78,469,740)	(191,280,386)	(122,032,906)
Profit for the Period	294,828,287	261,697,724	440,636,924	343,054,397
Earnings per share (EPS) - Basic and Diluted	1.29	1.11	1.93	1.52

M. Iqbal



[Signature]



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk